GlobeNewswire

University of Utah Health Extends 3D Printing to Physicians with TeraRecon

Dela

FOSTER CITY, Calif., Nov. 25, 2017 (GLOBE NEWSWIRE) -- University of Utah Hospitals & Clinics (healthcare.utah.edu), together with TeraRecon (www.terarecon.com), the market leading advanced visualization solution provider, today announced the launch of TeraRecon's 3D Print Pack Portal within the University of Utah Health's clinical environment, extending 3D printing access to physicians throughout the health system.

Surgeons and specialists throughout the University of Utah have been advocates and early adopters of 3D Printing technology for years, finding ways to reduce surgical time and improve patient outcomes.  As interest in the technology spread, physicians sought to provide better access to printing and improved clinical workflow, giving 3D Printing the runway to make faster, broader impact across more departments. 

TeraRecon's 3D Print Pack Portal is a direct extension of their iNtuition advanced visualization solution which is already a critical part of University of Utah's existing medical imaging workflow.  Users can segment imaging studies in their native tools and export for printing directly from iNtuition, without the need for any 3rd party segmentation tools or diminished file type conversions.  With TeraRecon's 3D Print Pack Portal, prints maintain full color and image detail exactly as they are displayed in the TeraRecon advanced visualization system.  Segmentations are uploaded to the Portal and exchanged for Print Pack Credits which are purchased on a subscription or bulk basis.  From the Portal, studies are ready for outsourced printing by WhiteClouds, the world's largest and most expert 3D printing provider.  This workflow model offers fast turn-around times, the widest variety of materials and printers on the market, and eliminates overhead costs typically associated with onsite 3D printing labs.

Dr. Edward P. Quigley III MD PhD, clinical neuro radiologist and Associate Professor of Radiology and Imaging Sciences at University of Utah shared, "We are excited to offer the TeraRecon 3D printing technology to our physicians across the health system. The multicolor models are high quality and incredibly life-like. They provide patient specific representation of anatomy and pathology.  They are a useful tool in the education of trainees and patient education. Patients really like seeing their model. 3D Prints help patients grasp their anatomy and treatment choices.  It can help de-mystify the often complex conventional CT and MR imaging.  We see this service as a great compliment to patient centered imaging and look forward to our growing partnership with TeraRecon to expand printing and visualization to new modalities and better patient care."

TeraRecon President & CEO, Jeff Sorenson states "The University of Utah has been a long-standing partner of TeraRecon as a customer of iNtuition and now with their market leading pursuit of 3D printing applications in medicine. We look forward to the ways 3D prints will be used to enhance patient care and collaboration among the physicians."

TeraRecon first launched their 3D Print Pack Portal at RSNA16 and have added a complementary Augmented Reality HoloPortal leveraging the same advanced technology.  Experience both by visiting TeraRecon at the 2017 Radiological Society of North America's Annual Meeting (RSNA17) at booth # 1332. 

About TeraRecon   (www.terarecon.com) TeraRecon is the largest independent, vendor neutral medical image viewing solution provider with a focus on advanced image processing innovation.  TeraRecon iNtuition solutions advance the accessibility, performance, clinical functionality and medical imaging workflow throughout many areas of the healthcare ecosystem. The company provides world class advanced visualization 3D post-processing tools, as well as a spectrum of enterprise medical image viewing, diagnostic interpretation, image sharing, cloud, interoperability and collaboration solutions.  TeraRecon is a privately-held company with its world headquarters in Foster City, California with major offices in Frankfurt, Germany; Tokyo, Japan; Acton, MA, and Durham, NC.

Press Inquiries:  US: 1-650-372-1100 | info@terarecon.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeraRecon, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum